Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Non-cash Items (2016 - 2024)

Trinity Biotech's Non-cash Items history spans 16 years, with the latest figure at -$9.3 million for Q4 2024.

  • On a quarterly basis, Non-cash Items fell 1.09% to -$9.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$9.3 million, a 1.09% decrease, with the full-year FY2024 number at -$9.3 million, down 1.09% from a year prior.
  • Non-cash Items hit -$9.3 million in Q4 2024 for Trinity Biotech, down from -$9.2 million in the prior quarter.
  • Over the last five years, Non-cash Items for TRIB hit a ceiling of $25.6 million in Q4 2020 and a floor of -$9.3 million in Q4 2024.
  • Historically, Non-cash Items has averaged $5.3 million across 5 years, with a median of $3.8 million in 2020.
  • Biggest five-year swings in Non-cash Items: soared 310472.95% in 2020 and later tumbled 1316.98% in 2023.
  • Tracing TRIB's Non-cash Items over 5 years: stood at $25.6 million in 2020, then plummeted by 32.03% to $17.4 million in 2021, then tumbled by 95.66% to $754000.0 in 2022, then tumbled by 1316.98% to -$9.2 million in 2023, then decreased by 1.09% to -$9.3 million in 2024.
  • Business Quant data shows Non-cash Items for TRIB at -$9.3 million in Q4 2024, -$9.2 million in Q4 2023, and $754000.0 in Q4 2022.